- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00079183
Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment
A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Sirolimus for Secondary Treatment of Chronic Graft-versus-Host Disease
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To assess the safety of sirolimus administered at a dose which provides steady-state, whole blood trough levels of 5-10 ng/mL in patients with chronic GVHD.
II. To determine whether administration of sirolimus provides benefit for patients with chronic GVHD that has not responded adequately to previous systemic treatment.
OUTLINE:
Patients receive sirolimus orally (PO) once daily (QD). Patients continue to receive prednisone and cyclosporine or tacrolimus at the discretion of the managing physician.
After completion of study treatment, patients are followed up periodically.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98109
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
Biopsy-confirmed diagnosis of clinical extensive chronic GVHD with inadequate response to previous treatment and where secondary systemic therapy is indicated because of
- Clinical progression of signs and symptoms of chronic GVHD in a previously involved organ, or
- Development of signs and symptoms of chronic GVHD in a previously uninvolved organ, or
- Absence of improvement after 3 months of primary treatment, or
- Continued need for treatment with prednisone at doses >= 1.0 mg/kg/day for more than 2 months, without qualification for type of donor, graft or conditioning regimen
- Patient or guardian able and willing to provide informed consent
- Stated willingness to use contraception in women of child-bearing potential (Food and Drug Administration [FDA] requirement)
- Stated willingness of the patient to comply with study procedures and reporting requirements
- Stated willingness of the physician most involved in management of chronic GVHD (the "managing physician,") to comply with study procedures and reporting requirements
Exclusion Criteria:
- Fungal or viral infection with no radiographic evidence of improvement during continued appropriate antimicrobial therapy
- Cytomegalovirus (CMV) antigenemia unresponsive to antiviral therapy
- Active disseminated varicella zoster virus (VZV) infection with persistent non-crusted lesions
- Inability to tolerate oral medications
- Absolute neutrophil count (ANC) < 1500/uL
- Platelet count < 50,000/uL
- Persistent or recurrent malignancy, including histopathologic evidence of myeloma or lymphoma; patients with breakpoint cluster region-abelson (bcr/abl) detected by polymerase chain reaction (PCR) assay as the only evidence of persistent chronic myeloid leukemia may be enrolled
- Pregnancy
- Known history of hypersensitivity to sirolimus
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Sirolimus
Study participants receive sirolimus added once daily to their baseline combination therapy of prednisone plus either cyclosporine or tacrolimus at the discretion of the managing physician.
Treatment other than cyclosporine (or tacrolimus) and prednisone must be discontinued when administration of sirolimus is started.
Topical therapy, including psoralen and UVA irradiation (PUVA), glucocorticoid creams, topical tacrolimus, oral beclomethasone, topical azathioprine and ophthalmic glucocorticoids may be given at the discretion of the managing physician in consultation with the transplant center.
|
Biorąc pod uwagę PO
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Number of Participants Experiencing Treatment Success
Ramy czasowe: Approximately 7 years
|
Defined as the absence of any immunosuppressive treatment, including sirolimus, with resolution of all reversible manifestations of chronic GVHD and no additional systemic therapy.
|
Approximately 7 years
|
Number of Participants Experiencing Treatment Failure
Ramy czasowe: Approximately 7 years
|
Defined as the initiation of additional systemic therapy, development of bronchiolitis obliterans, or death from causes other than recurrent malignancy during primary treatment for chronic GVHD, whichever occurs first.
|
Approximately 7 years
|
Number of Participants Needing Additional Systemic Therapy
Ramy czasowe: Approximately 7 years
|
Includes any intervention intended to control chronic GVHD through an immunosuppressive effect from oral or parenteral administration of any systemic medication not originally given under auspices of this protocol.
|
Approximately 7 years
|
Number of Participants With Recurrent Malignancy
Ramy czasowe: Approximately 7 years
|
Defined as clinical or histopathologic evidence demonstrating the presence of any malignancy considered as the indication for transplant.
Recurrent malignancy will also be defined as any post-transplant intervention not routinely used to prevent the development of overt recurrence, prompted by laboratory evidence of persisting malignant cells but without clinical or histopathologic evidence of recurrence.
|
Approximately 7 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Proportion of Patients Who Discontinue Administration of Sirolimus Because of Toxicity
Ramy czasowe: Approximately 7 years
|
Approximately 7 years
|
|
Proportion With Infections Categorized by Organism
Ramy czasowe: Approximately 7 years
|
Approximately 7 years
|
|
Secondary Malignancies
Ramy czasowe: Up to 7 years
|
Proportion of participants who developed at least one secondary malignancy by 7 years
|
Up to 7 years
|
Duration of Treatment With Prednisone
Ramy czasowe: Approximately 7 years
|
Approximately 7 years
|
|
Probability of Survival Without Recurrent Malignancy
Ramy czasowe: Approximately 7 years
|
Kaplan-Meier estimate assessed at 7 years for probability of survival without recurrent malignancy.
|
Approximately 7 years
|
Probability of Overall Survival
Ramy czasowe: Approximately 7 years
|
Kaplan-Meier estimate assessed at 7 years
|
Approximately 7 years
|
Probability of Cumulative Incidence of Death Without Recurrent Malignancy
Ramy czasowe: Approximately 7 years
|
Analyzed with recurrent malignancy as a competing risk factor.
Assessed at 7 years.
|
Approximately 7 years
|
Probability of Cumulative Incidence of Recurrent Malignancy
Ramy czasowe: Approximately 7 years
|
Analyzed with death as a competing risk factor.
Assessed at 7 years.
|
Approximately 7 years
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 1706.00
- NCI-2011-01817 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na syrolimus
-
Aadi Bioscience, Inc.ZakończonyGlejak nawrotowy wysokiego stopnia i nowo zdiagnozowany glejak wielopostaciowyStany Zjednoczone
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... i inni współpracownicyNieznany
-
Shanghai Jiao Tong University School of MedicineNieznany
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaZakończony
-
Nanjing First Hospital, Nanjing Medical UniversityWycofane
-
OrbusNeichCCRF Inc., Beijing, China; OrbusNeich Medical (Shenzhen), Co. Ltd.Zakończony
-
Aadi Bioscience, Inc.Zatwierdzony do celów marketingowychTSC1 | TSC2 | PEComa, złośliwy | Aberracja ścieżki mTOR
-
Instituto Nacional de Cardiologia Ignacio ChavezRekrutacyjnyChoroba wieńcowa | Przezskórna interwencja wieńcowa | Wysokie ryzyko krwawieniaMeksyk
-
Meril Life Sciences Pvt. Ltd.NieznanyChoroba wieńcowaZjednoczone Królestwo, Brazylia, Hiszpania, Macedonia, była jugosłowiańska republika, Belgia, Czechy, Łotwa, Holandia, Polska
-
Beijing Anzhen HospitalNieznany